Lv2
130 积分 2024-04-15 加入
Consensus on the lung cancer management after third-generation EGFR-TKI resistance
26天前
已完结
Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment
1个月前
已关闭
Chemical Dissection of Selective Myeloid Leukemia-1 Inhibitors: How They Were Found and Evolved
1个月前
已完结
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer
2个月前
已完结
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
2个月前
已完结
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
2个月前
已完结
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2个月前
已完结
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis
3个月前
已完结
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study
3个月前
已完结
皖公网安备34019202002308
